Sphingosine-1-phosphate (S1P) receptor modulators: amiselimod, ozanimod, etrasimod and fingolimod. Antiadhesion agents: vedolizumab, etrolizumab and ontamalimab. The microRNA-124 agent is obefazimod.

The launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key information in its application to the Food and Drug Administration (FDA).

Late-stage ozanimod trials are ongoing in ulcerative ... with Merck KGaA’s Mavenclad (cladribine), which has a difference mechanism of action but was cleared for the same indications by the ...

Orphagen Pharmaceuticals Receives NIH Funding Award to Advance a Novel Drug for Inflammatory Bowel Disease Funding to support preclinical development of Orphagen’s lead IBD candidate, OR-812, a ...